A heteropolysaccharide designated SLPC-1S with the Mw of 9.4 kDa was purified from the caps of Suillellus luridus. Monosaccharide composition analysis revealed that SLPC-1S was composed of galactose, glucose, arabinose and mannose in a molar ratio of 44.9:27.6:14.7:12.8. Structural characterization indicated that SLPC-1S had a backbone principally composed of 1,3 linked α-D-Galp, 1,3 linked β-D-Glcp and 1,6 linked β-D-Glcp with the branches mainly composed of 1,3 linked β-D-Glcp, 1,3 linked α-L-Arap, 1,3 linked α-D-Manp and T-linked α-D-Galp. Furthermore, SLPC-1S exhibited excellent antidiabetic activities in the streptozotocin-induced diabetic mice. Protein expression and mRNA levels in NF-kB and Nrf2/HO-1 signaling pathways were detected by western blots and real-time polymerase chain reaction (RT-PCR), respectively. The results strongly proved that SLPC-1S can be treated as a potential agent for preventing and treating diabetes via regulating Nrf2-mediated oxidative stress and NF-κB-mediated inflammatory responses.

从Suillellus luridus的帽中纯化出分子量为9.4 kDa的杂多糖SLPC-1S 。单糖组成分析表明，SLPC-1S由半乳糖，葡萄糖，阿拉伯糖和甘露糖组成，摩尔比为44.9：27.6：14.7：12.8。结构表征表明，SLPC-1S有主要由1,3-连接的α-d-Gal的骨干p，1,3-连接的β-d-GLC p和1,6-连接的β-d-GLC p与分支主要由1,3-连接的β-d-GLC p，1,3连接的α-L-阿拉p，1,3连接的α-d-曼p和T联α-d-Gal的p。此外，SLPC-1S在链脲佐菌素诱导的糖尿病小鼠中表现出优异的抗糖尿病活性。分别通过蛋白质印迹和实时聚合酶链反应（RT-PCR）检测NF-kB和Nrf2 / HO-1信号通路中的蛋白表达和mRNA水平。结果强烈证明SLPC-1S可以通过调节Nrf2介导的氧化应激和NF-κB介导的炎症反应作为预防和治疗糖尿病的潜在药物。